|
CA2542327A1
|
|
Combination therapy for cancer
|
|
CA2470908A1
|
|
Therapy for cancer
|
|
WO2004028475A2
|
|
Glycosylceramide analogues
|
|
WO03094850A2
|
|
Lipid a and other carbohydrate ligand analogs
|
|
EP1474432A1
|
|
Immunostimulatory, covalently lipidated oligonucleotides
|
|
CA2454853A1
|
|
Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier
|
|
EP1377275A2
|
|
Vaccine for modulating between t1 and t2 immune responses
|
|
AU2002219998B2
|
|
Preparation of large liposomes by infusion into peg
|
|
AU1764701A
|
|
Synthetic Lipid-A analogs and uses thereof
|
|
CA2354644A1
|
|
Muc-1 antagonists and methods of treating immune disorders
|
|
WO0000828A1
|
|
Method of detecting t-cell activation
|
|
EP1369428A1
|
|
Muc-1 derivatives and their use in treating cancer-associated MUC-1 Mucin-induced immunosuppression
|
|
EP1027373A1
|
|
Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
|
|
CA2302472A1
|
|
Randomly generated glycopeptide combinatorial libraries
|
|
WO9850527A1
|
|
Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
|
|
WO9810783A1
|
|
Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
|
|
WO9529927A2
|
|
Process for preparation of glycosides of tumor-associated carbohydrate antigens
|
|
AU2247095A
|
|
Cellular immune response-specific antigens and uses therefor
|
|
US5527891A
|
|
Stereodirected process for synthesis of α-N-acetylgalactosaminides
|
|
CA2137561A1
|
|
Photoactivation of proteins for conjugation purposes
|
